XML 38 R13.htm IDEA: XBRL DOCUMENT
v3.25.4

ADDITIONAL BALANCE SHEET DETAIL | 12 Months Ended
--- | ---
Dec. 31, 2025
Payables and Accruals [Abstract] |
ADDITIONAL BALANCE SHEET DETAIL | ADDITIONAL BALANCE SHEET DETAIL Prepaid expenses and other current assets are as follows (in thousands):
|  | December 31,
Description |  | 2025 |  | 2024
Prepaid manufacturing |  | — |  |  | 4,029 |
Restricted cash |  | 1,699 |  |  | — |
Other |  | 3,771 |  |  | 7,321 |
Total prepaid expenses and other current assets |  | 5,470 |  |  | 11,350 |
Prepaid manufacturing expenses include advance payments to contract manufacturing organizations, or CMOs, for APIs or drug substance. Such amounts are reclassified to work-in-process inventory upon the quality release of the batches and transfer of title to the Company from the CMO. Other prepaid expenses and other current assets, among other things, include capitalized implementation costs, prepaid insurance and prepaid information technology costs. Other long-term assets are as follows (in thousands):
|  | December 31,
Description |  | 2025 |  | 2024
Long-term inventories |  | $ | 59,129 |  |  | $ | 34,953 |
Restricted cash |  | — |  |  | 1,680 |
Other |  | 552 |  |  | 744 |
Total other long-term assets |  | $ | 59,681 |  |  | $ | 37,377 |
See Note 4, Inventories, for further information on long-term inventories. Accrued expenses and other current liabilities are as follows (in thousands):
|  | December 31,
Description |  | 2025 |  | 2024
Product revenue allowances |  | $ | 7,916 |  |  | $ | 9,657 |
Product rebates |  | 64,674 |  |  | 6,070 |
Product return provisions, current portion |  | 2,375 |  |  | 5,295 |
Compensation and related benefits |  | 11,018 |  |  | 9,194 |
Operating lease liabilities, current portion |  | 3,548 |  |  | 5,400 |
Royalties due to Panion & BF Biotech, Inc. |  | 3,924 |  |  | 3,543 |
Liability related to sale of future royalties, current portion |  | 1,664 |  |  | 2,039 |
Professional fees |  | 1,597 |  |  | 1,452 |
Accrued manufacturing costs |  | 1,808 |  |  | 1,468 |
BioVectra, Inc. termination fees, current portion |  | — |  |  | 7,204 |
Settlement royalties liability, current portion |  | 12,516 |  |  | 5,924 |
Clinical trial costs |  | 1,188 |  |  | 1,885 |
Restructuring costs, current portion |  | — |  |  | 489 |
Payments due to Q32 |  | 5,000 |  |  | — |
Other |  | 4,488 |  |  | 3,840 |
Total accrued expenses and other current liabilities |  | $ | 121,716 |  |  | $ | 63,460 |

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PayablesAndAccrualsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration